← Back to all trials
Recruiting
NCT07463846
A Study to Evaluate ALN-2232 in Participants With Obesity
Conditions: Obesity
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: PHASE1, PHASE2
Enrollment: 156
Sponsor: Alnylam Pharmaceuticals
Location: Clinical Trial Site Mount Royal
Summary
The purpose of this study is to:
* evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity
* evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity
* evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
Eligibility Criteria
Inclusion Criteria:
All Parts:
* Has a body mass index (BMI) of ≥30 kg/m\^2 and \
Source: ClinicalTrials.gov (NCT07463846). StuddyBuddy aggregates publicly available trial information.
